Guillain-Barré Syndrome Warning Added to Shingrix Vaccine in Australia
In February 2024, Australia’s Therapeutic Goods Administration (TGA), the country’s national regulatory authority for drugs and, initiated an investigation into a potential association between GSK plc’s Shingrix shingles vaccine, Guillain-Barré syndrome (GBS), which causes inflammation and damage to the nerves, that may include paralysis.1 The investigation was prompted by two reports of GBS following Shingrix […]
Pfizer Ends Development of Weight-Loss Pill After Liver Injury in Trial Participant
Pfizer, Inc. announced that it is discontinuing development of its experimental daily weight loss pill after a trial participant suffered a liver injury potentially linked to the drug. The company confirmed that the oral GLP-1 drug, danuglipron (PF-06882961), is no longer in development following the incident.1 Pfizer has been studying danuglipron since 2022.2 A Pfizer […]
Swedish Study Investigates Food Allergy Increases in Children But Big Questions Remain
An estimated 1 in 13 children in the United States now have food allergies, a 50 percent increase in the incidence of food allergies between 1997 and 2011. Food allergy researchers have suggested there are several factors contributing to this increase, including shifts toward more processed diets, insufficient levels of vitamin D from limited sun […]
FDA Recalls Acne Products Contaminated with Benzene Carcinogen
On Mar. 11, 2025, the U.S. Food and Drug Administration (FDA) alerted the public and industry about the results of its recent testing on 95 over-the-counter acne products containing benzoyl peroxide for possible contamination with benzene, a carcinogen. The agency determined that a limited number of acne products should be recalled from retail shelves.1 Human […]
NIH Cuts Funding for “Vaccine Hesitancy” Research
Certain areas of research funded by the U.S. National Institutes of Health (NIH) is being reduced or discontinued with the justification that these areas no longer align with the agency’s current priorities. One of the areas in which funding will be cut is millions of dollars in NIH grants for studying vaccine hesitancy and strategies […]
Glenmark Pharmaceuticals Recalls 1.5 Million Bottles of Generic ADHD Drug
Glenmark Pharmaceuticals, Inc., a subsidiary of Glenmark Pharmaceuticals Ltd. of Mumbai, India, is recalling 1.476 million bottles of a generic Attention Deficit Hyperactivity Disorder (ADHD) medication called atomoxetine from the U.S market, according to the U.S. Food and Drug Administration (FDA).1 Eli Lilly had once marketed the branded version of the drug, Strattera, but stopped […]